IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 28.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 451,636 shares of the medical research company's stock after selling 182,031 shares during the period. Nuveen Asset Management LLC owned approximately 0.25% of IQVIA worth $88,751,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of IQV. Smith Group Asset Management LLC acquired a new position in IQVIA during the 4th quarter worth $1,616,000. Hickory Asset Management Inc. acquired a new position in shares of IQVIA during the fourth quarter worth about $941,000. Fifth Third Bancorp increased its stake in shares of IQVIA by 13.0% during the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock worth $2,590,000 after buying an additional 1,521 shares during the period. Graphene Investments SAS raised its holdings in IQVIA by 22.0% in the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock valued at $2,948,000 after acquiring an additional 2,700 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Performance

NYSE IQV traded down $7.61 during trading hours on Wednesday, hitting $137.34. 2,870,722 shares of the stock were exchanged, compared to its average volume of 1,541,678. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a 50-day moving average of $158.26 and a 200 day moving average of $184.98. The company has a market cap of $23.76 billion, a price-to-earnings ratio of 18.31, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. IQVIA's revenue was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.54 earnings per share. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of recent analyst reports. Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday. Finally, Hsbc Global Res cut IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $228.14.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.